Case study backs Argent's cannabinoid for epilepsy
Peer-reviewed case report published in International Journal of Clinical Medicine & Case Reports
Significant reduction in seizure frequency and severity following treatment with reported improved quality of life
Special Report: Publication of a peer-reviewed case report highlights the therapeutic potential of Argent BioPharma's proprietary cannabinoid therapy CannEpil in treatment-resistant epilepsy.
The article titled Management of Lennox-Gastaut Syndrome with a CBD/THC Isolate Combination was published in the International Journal of Clinical Medicine & Case Reports.
It details the successful treatment of a paediatric patient with Lennox-Gastaut Syndrome (LGS) using CannEpil, a proprietary CBD/THC isolate formulation produced under EU-GMP standards by Argent BioPharma (ASX:RGT).
LGS is a severe and complex form of epilepsy that typically begins in early childhood and is characterised by multiple types of seizures, developmental delays and its resistance to standard anti-epileptic treatments.
The study, authored by Argent's VP of medical development Dr Jonathan Grunfeld and medical researcher Dr Jasna Jarc, describes a significant improvement in the patient's condition and quality of life, including:
A reduction in seizure clusters and daily seizure frequency;
Recovery of speech, fine motor skills and independent mobility; and
Reintegration into a full-time educational environment
Case study builds evidence for CannEpil's clinical and strategic potential
Argent said the latest peer-reviewed case study added to the growing body of real-world evidence supporting CannEpil's application in complex epilepsy syndromes.
It also highlights the advantages of using pharmaceutical-grade isolate combinations over full-spectrum botanical preparations, providing more precise dosing and improved safety profiles.
The case study also aligns with the indication for Epidiolex, which is currently the only US Food and Drug Administration (FDA) approved cannabinoid treatment for LGS.
The milestone regulatory approval underpinned Nasdaq-listed Jazz Pharmaceuticals' ~US$7.2 billion acquisition of Epidolex's developer in 2021 GW Pharmaceuticals plc.
While CannEpil is not yet positioned to compete with Epidiolex on regulatory validation, Argent said the therapy was emerging as a potential next-generation cannabinoid treatment for refractory epilepsy, particularly in patients who did not respond to CBD-only formulations.
Supported by clinical case data and head-to-head comparative research, CannEpil aims to deliver meaningful seizure reduction, improved quality of life and better patient tolerability at lower doses, while maintaining pharmaceutical-grade consistency.
"This case exemplifies the transformative impact a rigorously formulated cannabinoid therapy can have on patients for whom standard treatments have failed,' Grunfeld said.
'CannEpil's precision, purity and clinical consistency are central to its success."
This article was developed in collaboration with Argent BioPharma, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
21 hours ago
- ABC News
Toxoplasmosis test could lead to learning how parasite affects behaviour
An international research team has developed an online test that they say is capable of detecting toxoplasmosis infection, commonly spread to humans by cats. While the test is not designed to replace a medical diagnosis, the researchers hope it will open the door for more large-scale studies into the effects of toxoplasmosis on the population. An estimated 30 to 50 per cent of the world's population is infected with Toxoplasma gondii, a single-celled parasite capable of infecting humans and any warm-blooded animal or bird. In Australia, the main host of the parasite is cats, which typically become infected by eating small mammals such as rodents or birds. The disease associated with the parasite, toxoplasmosis, can cause a range of health problems, from minor flu-like symptoms to, in rare cases, inflammation of the brain, seizures, and blindness. Toxoplasmosis can alter behaviour in animals, and some research suggests it may also affect how humans think. A new international study published in Acta Psychologica may provide a new way to study these effects. According to neuroeconomist Michele Garagnani, from The University of Melbourne and study co-author, toxoplasmosis affects our neurochemistry by influencing neurotransmitters such as dopamine, serotonin, and adrenaline, which regulate behaviour. Unlike many parasitic infections, being infected with T. gondi has been linked to a range of mental health conditions and behavioural changes, including bipolar disorder, delayed reaction times, and schizophrenia. The infection has been found to make mice impatient and willing to take risks. In some cases, mice actively seek out cats, which makes them more likely to be eaten. While it is still unknown how the parasite causes these changes, it raises important questions about the broader impacts of toxoplasmosis on human health and behaviour. "When we estimate that toxoplasmosis affects 2.4 billion people worldwide, that's a very large portion of the global economy who are having their decisions at least partially influenced by a parasite," Dr Garagnani said. Much about how toxoplasmosis affects human behaviour remains unknown. One major obstacle is that medical testing for the parasite is expensive and invasive, requiring blood or saliva samples. "Our research was trying to develop a method that is very cheap and easy to test on a large number of people," Dr Garagnani said. In the study, researchers ran a laboratory experiment with 79 participants with RhD-negative blood lacking the RhD protein on the surface of red blood cells, asking them to complete a reaction-time task. People with the RhD-negative blood type, about 20 per cent of Australians, have slower response times when infected by the parasite. While it is unclear why RhD-negative individuals have slower reaction times when infected, some theorise that the RhD antigen has protective capabilities against the parasite, and in its absence, patients experience elevated symptoms. Despite the small sample size, the team found that their method matched medical testing with 97 per cent accuracy. The delay in reaction time is small, between 0.16 and 0.25 seconds, but Dr Garagnani said even marginal effects could have large-scale consequences. "On a societal scale, having toxoplasmosis infection with that particular blood type leads to an increase in traffic accidents, for example," he said. The team then replicated the experiment using an online survey with more than 1,000 participants in the UK who had RhD-negative blood. Based on the results, the research team deemed 18 per cent of the respondents to be infected with toxoplasmosis. The team then asked participants a series of questions about their risk preferences, employment status, income, and completed other cognitive tests. "Those who were deemed infected were more likely to smoke, drink alcohol, and experience mental health problems such as anxiety, stress and depression compared to the non-infected participants," Dr Garagnani said. While the new online test does not replace a medical diagnosis, Dr Garagnani hoped it would allow researchers to measure the impact of toxoplasmosis on humans. "Our new method is an opportunity for the world as a whole to understand how many of us are infected, how it affects our behaviour, and what steps we can take to manage its impact," he said. Veterinary parasitologist Tharaka Liyanage said the study posed an innovative approach to exploring the potential behavioural consequences of an infection. "I find it fascinating that a microscopic cat parasite could influence not only human health, but also cognition, behaviour, and even economic decision-making," he said. "This tool may be particularly useful in low-resource settings or as a preliminary step in large-scale epidemiological studies." But, Dr Liyanage cautioned that a lot of work needed to be done before the tool made its way into a clinical setting. "I believe further validation, particularly in consultation with medical and clinical experts, would be necessary before this method can be considered for broader application." The test also requires people to have RhD-negative blood, which only 15 to 20 per cent of people have. Rima McLeod, an internationally recognised toxoplasmosis expert from the University of Chicago, echoed this sentiment and called for further research. "Proper, accurate serologic controls documenting toxoplasma infection or its absence for each participant would be needed to implicate toxoplasma in the associations they propose," Professor McLeod said. Dr Garagnani hoped to conduct further tests on the diagnostic tool. "We are hoping that with future study we verify further that the method works, and whether it could be used as a public policy type of intervention where we could firstly test for toxoplasmosis using our method and then try to understand how to effectively target the population where the prevalence is more diffuse."
The Australian
2 days ago
- The Australian
Case study backs Argent's cannabinoid for epilepsy
Case report shows clinical benefits of Argent's CannEpil in a paediatric patient with Lennox-Gastaut Syndrome Peer-reviewed case report published in International Journal of Clinical Medicine & Case Reports Significant reduction in seizure frequency and severity following treatment with reported improved quality of life Special Report: Publication of a peer-reviewed case report highlights the therapeutic potential of Argent BioPharma's proprietary cannabinoid therapy CannEpil in treatment-resistant epilepsy. The article titled Management of Lennox-Gastaut Syndrome with a CBD/THC Isolate Combination was published in the International Journal of Clinical Medicine & Case Reports. It details the successful treatment of a paediatric patient with Lennox-Gastaut Syndrome (LGS) using CannEpil, a proprietary CBD/THC isolate formulation produced under EU-GMP standards by Argent BioPharma (ASX:RGT). LGS is a severe and complex form of epilepsy that typically begins in early childhood and is characterised by multiple types of seizures, developmental delays and its resistance to standard anti-epileptic treatments. The study, authored by Argent's VP of medical development Dr Jonathan Grunfeld and medical researcher Dr Jasna Jarc, describes a significant improvement in the patient's condition and quality of life, including: A reduction in seizure clusters and daily seizure frequency; Recovery of speech, fine motor skills and independent mobility; and Reintegration into a full-time educational environment Case study builds evidence for CannEpil's clinical and strategic potential Argent said the latest peer-reviewed case study added to the growing body of real-world evidence supporting CannEpil's application in complex epilepsy syndromes. It also highlights the advantages of using pharmaceutical-grade isolate combinations over full-spectrum botanical preparations, providing more precise dosing and improved safety profiles. The case study also aligns with the indication for Epidiolex, which is currently the only US Food and Drug Administration (FDA) approved cannabinoid treatment for LGS. The milestone regulatory approval underpinned Nasdaq-listed Jazz Pharmaceuticals' ~US$7.2 billion acquisition of Epidolex's developer in 2021 GW Pharmaceuticals plc. While CannEpil is not yet positioned to compete with Epidiolex on regulatory validation, Argent said the therapy was emerging as a potential next-generation cannabinoid treatment for refractory epilepsy, particularly in patients who did not respond to CBD-only formulations. Supported by clinical case data and head-to-head comparative research, CannEpil aims to deliver meaningful seizure reduction, improved quality of life and better patient tolerability at lower doses, while maintaining pharmaceutical-grade consistency. "This case exemplifies the transformative impact a rigorously formulated cannabinoid therapy can have on patients for whom standard treatments have failed,' Grunfeld said. 'CannEpil's precision, purity and clinical consistency are central to its success." This article was developed in collaboration with Argent BioPharma, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
AU Financial Review
2 days ago
- AU Financial Review
Trump to hike India's tariff over Russian oil buys
President Donald Trump said he would be 'substantially raising' the tariff on Indian exports to the US over the Asian nation's purchases of Russian oil, a move New Delhi slammed as unjustified in an escalating fight between the two major economies. 'India is not only buying massive amounts of Russian Oil, they are then, for much of the Oil purchased, selling it on the Open Market for big profits,' Trump wrote on social media Monday. 'They don't care how many people in Ukraine are being killed by the Russian War Machine. Because of this, I will be substantially raising the Tariff paid by India to the USA.' Trump did not say by how much he would increase the levy. Last week, he announced a 25 per cent rate on Indian exports and vowed more duties if India continued to buy oil from Russia. The US president's warning comes ahead of an August 8 deadline for Russia to reach a truce with Ukraine, with the administration threatening so-called secondary sanctions on countries that purchase Russian energy. Ukraine's allies view those purchases as helping to prop up Russian leader Vladimir Putin's economy and undercutting pressure on Moscow to end a war that is now in its fourth year. India has been a top Trump target in the campaign to end the war. New Delhi has been defiant, however, with Prime Minister Narendra Modi — who previously enjoyed warm relations with Trump — responding by urging Indians to buy local goods and signalling that his country will continue to buy Russian oil. 'The targeting of India is unjustified and unreasonable,' said India's Ministry of External Affairs in a social media post later on Monday, accusing the EU and US of trading with Russia when it is 'not even a vital national compulsion.'
